A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Korábbi kezelés

• Prior solid organ transplantation
• Either of the following: a) Received an autologous stem cell transplant less than or equal (<=) 9 months before the first dose of study drug B) Prior treatment with allogenic stem cell transplant

Más betegség

• History of, or known, central nervous system (CNS) involvement
• History of malignancy (other than the disease under study) within 3 years before the first administration of study drug. Exceptions include squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
• Known allergies, hypersensitivity, or intolerance to JNJ-64619178 or its excipient

• B cell non-Hodgkin lymphoma (NHL) or solid tumors, or lower risk MDS
• At least 1 measurable site of disease for B cell-NHL and solid tumors
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Adequate organ function
• Women of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and prior to the first dose of study drug. Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after receiving the last dose of study drug